Real-world data (RWD) is defined as data derived from a number of sources that are associated with outcomes in a heterogeneous patient population in real-world settings.
The global real-world evidence market is valued at 612.0 million in 2017 and projected to reach USD 1,348.1 million by 2023, at a CAGR of 14.3%.
The growth of this market is majorly driven by the rising geriatric population (and the subsequent increase in the prevalence of chronic diseases), shift from volume- to value-based care, and delays in drug development (and the subsequent increase in development costs).
The rising focus on end-to-end RWE services and growth opportunities in emerging markets are expected to provide further growth opportunities for players operating in the real world evidence market.
However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection some of the factors limiting the growth of this market during the forecast period.
Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=76173991 Real World Evidence Market, By Component IntroductionData SetsClinical Setting DataClaims DataPharmacy DataPatient Powered DataServicesReal World Evidence Market, By Therapeutic Area OncologyCardiovascular DiseaseNeurologyImmunologyOthers Therapeutic AreasReal World Evidence Market, By End User Pharmaceutical and Medical Device CompaniesHealthcare PayersHealthcare ProvidersOther End UsersReal world evidence Market, By Region North AmericaUSCanadaEuropeGermanyUKFranceItalySpainRest Of EuropeAsia Pacific (APAC)ChinaJapanRest of APACRest of the WorldKey Players The prominent players in the global real world evidence solutions market are IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US).